AHA 2019
CONTENTS
Online First
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results

Targeting LDL-C
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan

DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint

Inclisiran safely halves LDL-Cholesterol

Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves

RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies

New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
